



NGL Fine-Chem Limited

Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.
Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884, Website www.nglfinechem.com

February 7, 2025

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai — 400 001.
Scrip: 524774

To,
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No.C/1,
G Block, Bandra Kurla Complex,
Bandra East, Mumbai 400050.
Symbol: NGLFINE

Sub: Outcome of the Board Meeting Dated 7th February, 2025.

Dear Sir/Madam,

This is to inform you that the fourth Meeting of the Board of Directors of NGL Fine-Chem Limited for the Financial Year 2024-2025 held today i.e. on Friday, 7th February, 2025, where in Board has approved the Unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at www.nglfinechem.com.

The meeting of the Board of Directors commenced at 6.00 p.m. and concluded at 7.00 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited

Pallavi Satish Pednekar
Digitally signed by
Pallavi Satish Pednekar
Date: 2025.02.07
19:05:36 +05'30'

Pallavi Pednekar
Company Secretary & Compliance Officer
Membership No: A33498

NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle (East), Mumbai 400 057

CIN: L24110MH1981PLC025884

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2024



Part I: Statement of Consolidated and Standalone Unaudited Results for the Quarter and Nine months ended 31st December 2024

Rupees in lakhs

	Particulars	Consolidated						Standalone					
		Quarter Ended			Nine month Ended			Quarter Ended		Nine month Ended		Year Ended	
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)	31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
I	Revenue from Operations	8,909.88	9,348.39	8,795.15	27,333.62	23,922.67	33,866.64	6,603.17	9,140.99	8,481.25	26,027.60	23,336.44	32,897.29
II	Other Income	(13.19)	511.52	367.99	1,059.07	1,016.55	1,412.80	15.26	542.92	418.83	1,157.12	1,175.43	1,590.14
III	Total Revenue (I+II)	8,896.69	9,859.91	9,163.14	28,392.69	24,939.22	35,279.44	6,618.43	9,683.91	8,900.08	27,184.72	24,511.87	34,487.43
IV	Expenses :												
	a) Cost of Material Consumed	4,793.36	4,180.43	4,607.23	13,509.84	11,904.06	17,081.19	4,982.37	4,176.85	4,506.96	13,583.23	11,657.02	16,556.42
	b) (Increase)/Decrease in stock in trade and work in progress	(440.47)	237.11	(481.74)	(22.20)	(765.58)	(1,212.51)	(473.03)	303.16	(907.21)	40.09	(753.54)	(1,205.63)
	c) Employee benefits expenses	1,466.28	1,471.89	1,151.69	4,129.88	3,302.20	4,511.63	1,325.07	1,367.19	1,053.42	3,777.10	3,037.46	4,132.49
	d) Finance Costs	60.05	31.66	27.50	136.05	85.01	133.81	60.05	31.66	27.60	138.05	88.01	133.81
	e) Depreciation and amortisation expenses	309.90	302.70	294.29	915.06	860.15	1,164.18	229.62	230.20	206.74	673.76	608.33	814.79
	f) Other expenses	2,581.04	2,303.16	2,131.25	7,087.88	5,706.45	8,161.64	2,493.34	2,231.84	2,333.13	7,150.21	6,227.46	8,882.92
	Total Expenses (IV)	8,770.16	8,526.95	7,730.22	25,754.51	21,104.29	29,839.94	8,617.32	8,340.90	7,620.54	25,360.44	20,864.74	29,416.60
V	Profit/(loss) before exceptional items and tax (III-IV)	126.53	1,332.96	1,432.92	2,638.18	3,834.93	5,441.70	81.11	1,343.01	1,279.54	2,424.28	3,647.13	5,070.83
VI	Exceptional Items												
VII	Profit/(loss) Before Tax (V-VI)	126.53	1,332.96	1,432.92	2,638.18	3,834.93	5,441.70	81.11	1,343.01	1,279.54	2,424.28	3,647.13	5,070.83
VIII	Tax Expense												
	a) Current Tax	(116.00)	(277.50)	(282.00)	(615.00)	(821.00)	(1,182.50)	(115.00)	(262.50)	(255.00)	(560.00)	(785.00)	(1,112.90)
	b) Prior Years	2.38	-	(107.62)	2.38	(40.00)	(40.00)	-	-	(96.45)	-	(28.83)	(28.83)
	c) Deferred Tax	113.75	(74.19)	(39.94)	5.27	(72.09)	(97.53)	112.17	(70.00)	(36.49)	1.00	(66.22)	(77.56)
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	127.66	981.27	1,063.36	2,030.83	2,901.84	4,101.67	78.28	1,004.43	899.60	1,865.28	2,767.08	3,851.94
X	Other Comprehensive Income												
	a. Gain/(Loss) on actuarial valuation of post employment benefits	8.22	(40.11)	4.06	(30.61)	(19.74)	(20.42)	7.99	(39.21)	3.55	(30.77)	(20.26)	(20.47)
	b. Deferred tax on above	(2.10)	10.12	(1.02)	7.71	4.97	5.14	(2.01)	9.87	(0.89)	7.75	5.10	5.16
	c. Other Comprehensive Income (Net of Tax)	6.22	(29.99)	3.04	(22.90)	(14.77)	(15.28)	5.98	(29.34)	2.66	(23.03)	(15.16)	(16.32)
XI	Total Comprehensive Income	133.88	951.28	1,066.40	2,007.93	2,887.07	4,116.39	84.26	975.09	892.26	1,842.25	2,751.92	3,835.62
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90
XIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A.	N.A.	N.A.	N.A.	N.A.	25,971.64	N.A.	N.A.	N.A.	N.A.	N.A.	25,971.64
XIV	Earnings Per Share (EPS)												
	a) Basic	2.07	15.88	16.24	32.87	46.97	66.88	1.27	16.26	14.40	30.19	44.79	62.35
	b) Diluted	2.07	15.88	16.24	32.87	46.97	66.88	1.27	16.26	14.40	30.19	44.79	62.35

- Notes:
- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 7th February, 2025. These results are subjected to Limited Review by the Statutory Auditors of the Company.
 - The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2016.
 - The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
 - Previous period figures have been regrouped/rearranged wherever necessary.

For and on behalf of Board of Directors

 Rahul Nachane
 Managing Director

Place: Mumbai
 Date: 7th Feb 2025



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

3158 5697

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.

Cell : +91 93222 26311

MITTUL B. DALAL

B.Com. F.C.A.

Cell : +91 80973 74277

Review report to
The Board of Directors,
M/s.NGL Fine-Chem Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s.NGL Fine-Chem Limited** for the period ended **December 31, 2024**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK AND ASSOCIATES**

Chartered Accountants

Firm's Registration No.:**126679W**



MB Dalal

(MITTUL DALAL)

Partner

Membership Number:**172676**

UDIN: **25172676BMJLIB1201**

MUMBAI

Dated:**7th February, 2025**



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

3158 5697

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.

Cell : +91 93222 26311

MITTUL B. DALAL

B.Com. F.C.A.

Cell : +91 80973 74277

Independent Auditor's Review Report

To,
The Board of Directors,
M/s.NGL Fine-Chem Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s.NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/s.Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended **December 31, 2024** and for the period from **01st October 2024 to 31st December 2024** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s. Macrotech Polychem Private Limited, its wholly owned subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**
Chartered Accountants
Firm's Registration No.: **126679W**



Mittal Dalal

(MITTUL DALAL)
Partner

Membership Number: **172676**
UDIN: **25172676BMJLID9553**

MUMBAI

Dated : **7th February, 2025**